Physician profile
Laura E Minto
NPI 1386791259
$32,699.08
in general payments reported to CMS, 2019-2025
45 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $258 · 2021: $331 · 2022: $1,676 · 2023: $2,605 · 2024: $3,390 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,889 · Consulting Fee: $7,200 · Travel and Lodging: $202 · Education: $92.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,888.99 |
| Consulting Fee | $7,200.00 |
| Travel and Lodging | $202.31 |
| Education | $92.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14,102.24 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Emd Serono, INC. | $8,284.02 | 2019-2025 | Mavenclad |
| Abbvie INC. | $2,004.03 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,307.69 | 2019-2025 | |
| Pfizer INC. | $718.66 | 2023-2025 | |
| Lilly USA, LLC | $602.84 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Eisai INC. | $517.95 | 2019-2025 | |
| Sk Life Science, INC. | $493.54 | 2021-2025 | |
| Lundbeck LLC | $456.87 | 2022-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $448.52 | 2022-2025 | Nuplazid |
| Argenx US, INC. | $367.28 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $362.78 | 2021-2025 | Zeposia |
| Ucb, INC. | $355.78 | 2023-2025 | Zilbrysq, Briviact, Nayzilam |
| Biogen, INC. | $272.65 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Tg Therapeutics, INC. | $268.07 | 2023-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Minto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.